543635 and PPLPHARMA. Related Headlines
Go Back- Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
- Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
- Piramal Pharma Limited Announces Results for Q1FY26
543635 and PPLPHARMA. Related Press Releases
Go Back- Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions' Bioconjugates Facility in Grangemouth, UK Receives Updated MHRA GMP Certificates
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
- Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
- Piramal Pharma Limited Announces Results for Q1FY26
